An Invasive Method for the Activation of the Mouse Dentate Gyrus by High-frequency Stimulation
June 2nd, 2018
7.3K views
This protocol shows how to set up a reliable HFS method in mice. Neurons throughout the hippocampal dentate gyrus are electrically stimulated by HFS directly and indirectly in vivo. Neuronal activity and molecular signaling are examined by c-fos and Notch1 immunofluorescent staining, respectively; neurogenesis is quantified by bromodeoxyuridine labeling assay.
Overview
This study outlines a protocol to investigate the effects of high-frequency stimulation (HFS) on neuronal activity and neurogenesis in the hippocampus of mice. It highlights how HFS affects molecular signaling and neuronal activity through specific staining methods.
Key Study Components
Area of Science
- Neuroscience
- Neurogenesis
- Electrophysiology
Background
- High-frequency stimulation (HFS) can influence neuronal activity and neurogenesis.
- The hippocampal dentate gyrus is crucial for understanding these processes.
- Molecular signaling mechanisms can be assessed using specific immunofluorescent staining techniques.
- This method may extend to other brain systems relevant to clinical disorders.
Purpose of Study
- To assess the effects of HFS on neuronal activation and neurogenesis in a mouse model.
- To explore the underlying cellular and molecular mechanisms associated with high-frequency deep brain stimulation.
- To provide insights applicable not only to neurogenesis but also to other regions implicated in brain disorders.
Methods Used
- In vivo HFS protocol using anaesthetized mice.
- Electrodes are implanted in the hippocampal dentate gyrus.
- Utilization of c-fos and Notch1 immunofluorescent staining for assessing neuronal activity.
- Bromodeoxyuridine (BrdU) labeling assay to quantify neurogenesis.
- The timeline involves multiple phases including recovery, stimulation, and post-stimulation analysis of brain tissues.
Main Results
- Electrical stimulation resulted in significant changes in neuronal activity as indicated by c-fos expression.
- Notch1 signaling was linked with neurogenesis in response to HFS.
- BrdU labeling showed quantifiable evidence of neurogenesis under defined stimulation conditions.
- The methodology established provides a framework for further exploration of brain stimulation effects in neurological research.
Conclusions
- This study demonstrates the utility of HFS for investigating neuronal mechanisms in the hippocampus.
- Understanding the relationship between neuronal activity and neurogenesis could have implications for treating neurological disorders.
- The results support the development of HFS applications in various brain models, enhancing our knowledge of neuronal plasticity.
Frequently Asked Questions
What are the advantages of using high-frequency stimulation in mice?
High-frequency stimulation allows researchers to induce and measure neuronal activation more effectively in a controlled in vivo environment, leading to better insights into neurogenesis and the role of synaptic plasticity.
How is the biological model implemented?
The biological model involves implanting electrodes in the hippocampal region of anesthetized mice, followed by delivering precise electrical stimulation protocols to activate neuronal pathways.
What types of outcomes does the study measure?
The study measures molecular signaling changes through c-fos and Notch1 expression, as well as quantifies neurogenesis using BrdU labeling techniques.
How can this method be applied to other brain regions?
While the primary focus is on the hippocampus, the technique can be adapted for deeper brain structures like the basal ganglia and subthalamic regions in both experimental and clinical contexts.
What are the limitations of this study?
Potential limitations include the use of anesthetized mice, which may not fully reflect natural neuronal responses, and variations in stimulation parameters that require careful optimization.
What critical steps are in the timeline for this procedure?
Key steps include preparing the animal, implanting electrodes, delivering stimulation, allowing recovery, and conducting post-stimulation analyses such as tissue fixation and staining.
Executive Industry Relevance
This method enables mechanistic de-risking of high-frequency deep brain stimulation (HF-DBS) by linking stimulation parameters to quantifiable neurogenic and neuronal activity outcomes in a disease-relevant system. It supports target validation and assay development for neuropsychiatric indications such as major depressive disorder and obsessive-compulsive disorder by providing predictive confidence in downstream translational pathways. The approach establishes a preclinical model for evaluating biological effects of neuromodulation prior to lead identification or clinical candidate advancement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses by measuring c-fos and Notch1 signaling as proxies for neuronal activation and pathway modulation.
- Operational Value: Enables functional target validation through BrdU-labeled neurogenesis quantification in the dentate gyrus, a disease-relevant system for hippocampal-dependent disorders.
- Predictive Value: Supports predictive confidence by establishing dose-response relationships between stimulation frequency, duration, and neurogenic output.
Screening & Assay Development
- Assay Readiness: Prepares standardized brain slice preparations for immunofluorescent staining, enabling reproducible quantification of c-fos, Notch1, and BrdU as multiplexed readouts.
- Quantitative Output: Delivers measurable dependent variables (cell counts, fluorescence intensity) that support assay standardization and cross-group comparisons.
- Screening Scalability: Facilitates preparation of validated biological systems for downstream compound or modulator screening in chronic stimulation paradigms.
Translational & Preclinical Research
- Disease Relevance: Models hippocampal neurogenesis alterations relevant to major depressive disorder and cognitive comorbidities in neuropsychiatric indications.
- Translational Continuity: Bridges acute and chronic stimulation paradigms to assess delayed neurogenic responses, mirroring clinical timelines of therapeutic onset.
- Mechanistic De-risking: Clarifies whether observed behavioral effects stem from neurogenesis versus acute neuronal activation, reducing ambiguity in target engagement.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target hypothesis testing through preclinical validation, particularly for neuromodulation strategies targeting hippocampal circuitry in mood and cognitive disorders.
- Discovery Biology: Supports hypothesis testing by isolating the dentate gyrus as a site of stimulation-induced neurogenic and transcriptional response.
- Screening: Enables assay development for compounds that may potentiate or mimic HF-DBS-induced neurogenesis via BrdU and Notch1 readouts.
- Analytics: Provides quantitative dependent variables (BrdU+ cell density, c-fos+ neuron percentage) for statistical comparison across stimulation groups.
- Translational Research: Connects stimulation protocols to disease-relevant neurogenic outcomes, supporting risk-adjusted advancement decisions.
- Enterprise Reuse: Establishes a reusable surgical and staining platform applicable to other brain regions (e.g., basal ganglia, subthalamic nucleus) for indication expansion.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by linking stimulation to defined molecular (Notch1) and cellular (BrdU, c-fos) endpoints.
- Operational Value: Standardizes electrode implantation, stimulation delivery, and tissue processing for reproducible neurogenic assessment across laboratories.
- Strategic Value: Improves go/no-go decisions by providing early evidence of target engagement and biological effect magnitude.
- Portfolio Impact: Enables risk-adjusted prioritization of neuromodulation approaches based on validated neurogenic and signaling outcomes.
Implementation Considerations
- Requires expertise in stereotactic surgery, electrophysiology, and histological processing for immunofluorescent staining.
- Dependent on instrumentation including stereotactic frames, programmable stimulators, cryostats, and fluorescence microscopy systems.
- Necessitates cross-team standardization of stimulation parameters, BrdU dosing schedules, and antibody validation for consistent readouts.
- Involves adaptation considerations when targeting non-hippocampal regions due to anatomical variability in electrode placement and tissue accessibility.
- Practical limitations include survival surgery variability, staining quantification subjectivity, and the need for sham-stimulated controls to isolate stimulation-specific effects.
Biopharma FAQs
Why does c-fos staining matter for target validation?
c-fos staining serves as a quantitative dependent variable to confirm neuronal activation following high-frequency stimulation, providing a direct readout of target engagement in the dentate gyrus. Its expression levels enable comparison between stimulated and control groups to assess the biological effect of stimulation parameters.
How does BrdU labeling enable neurogenesis quantification?
BrdU labeling measures DNA synthesis in proliferating progenitor cells, allowing quantification of newly generated neurons in the dentate gyrus after stimulation. Increased BrdU+ cell counts in stimulated versus control groups indicate enhanced neurogenic activity as a downstream effect of HF-DBS.
What role does Notch1 signaling play in mechanistic de-risking?
Notch1 immunofluorescent staining assesses molecular pathway activation linked to neuronal differentiation and neurogenic response, helping distinguish between proliferation and maturation stages. Its co-localization with BrdU+ cells supports mechanistic insights into how stimulation influences neurogenic cascades.
Why are replication requirements critical for cross-functional collaboration?
Replication across acute and chronic stimulation groups ensures that observed neurogenic effects are consistent and not due to procedural variability, supporting reliable data transfer between discovery and preclinical teams. Standardized BrdU dosing and fixation timelines enable comparable results across laboratories.
What statistical analysis is required before implementation?
Implementation requires group-wise comparison of BrdU+ cell densities, c-fos+ neuron percentages, and Notch1 signal intensity using appropriate parametric or non-parametric tests to determine statistical significance. Power analysis based on expected effect sizes from pilot data is necessary to define group sizes and detect meaningful differences.
